Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Levin

Showing results (171-180 of 217) with videos related to

Pageof 22
Sort By:
Haematologica|October 20, 2022
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET studyFrançoise Kraeber-Bodéré, Sonja Zweegman, Aurore Perrot, et al.
The Lancet. Haematology|October 7, 2018
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trialNiels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, et al.
The Lancet. Oncology|June 2, 2022
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trialArnon P Kater, Mark-David Levin, Julie Dubois, et al.
Hemasphere|July 5, 2024
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomesKazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Pulmonary Circulation|March 19, 2019
EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)David G Kiely, David Levin, Paul Hassoun, et al.
Hemasphere|October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levelsWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere|December 10, 2025
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcomeKazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Haematologica|August 18, 2018
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemiaArnon P Kater, Marinus H J van Oers, Yvette van Norden, et al.
Hemasphere|September 4, 2023
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13Kazimierz Groen, Fredrik H Schjesvold, Bronno van der Holt, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Pageof 22

Showing results (171-180 of 217) with videos related to

Sort By:
Pageof 22
Haematologica|October 20, 2022
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET studyFrançoise Kraeber-Bodéré, Sonja Zweegman, Aurore Perrot, et al.
The Lancet. Haematology|October 7, 2018
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trialNiels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, et al.
The Lancet. Oncology|June 2, 2022
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trialArnon P Kater, Mark-David Levin, Julie Dubois, et al.
Hemasphere|July 5, 2024
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomesKazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Pulmonary Circulation|March 19, 2019
EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)David G Kiely, David Levin, Paul Hassoun, et al.
Hemasphere|October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levelsWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere|December 10, 2025
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcomeKazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Haematologica|August 18, 2018
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemiaArnon P Kater, Marinus H J van Oers, Yvette van Norden, et al.
Hemasphere|September 4, 2023
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13Kazimierz Groen, Fredrik H Schjesvold, Bronno van der Holt, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Pageof 22